About the Company
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.
ADMA also operates ADMA BioCenters, an FDA-licensed source plasma collection facility which provides a portion of blood plasma for the manufacture of the Company’s lead product candidate
ADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016
RAMSEY, N.J., Dec. 09, 2015 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA), announced today the expansion of its commercial operations team, appointing Alan Erck as the Company’s Vice President, Sales and National Accounts. ADMA Biologics is a late-stage biopharmaceutical...
RAMSEY, N.J., Dec. 03, 2015 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is...